Hoffman's decade-long tenure on Microsoft board ends

Reid Hoffman, the co-founder of LinkedIn, is stepping down from Microsoft's board of directors after serving for a decade. The company made the announcement on Thursday, marking the end of a period that saw Hoffman play a key role in some of Microsoft's most significant strategic moves. He joined the board in 2016 after Microsoft acquired LinkedIn for $26.2 billion, a deal that reshaped the social networking landscape. During his tenure, Hoffman was instrumental in Microsoft's early bet on artificial intelligence, notably when the tech giant invested its first $1 billion into OpenAI in 2019. That investment has since grown into a multi-billion-dollar partnership, fueling the development of models like GPT-4 and Copilot. Hoffman's departure comes as he shifts his focus to a new venture in the biotech space.

From Inflection AI to Manus: Hoffman's AI pivot

Hoffman's relationship with AI has been both influential and, at times, controversial. He was an early investor in OpenAI and served on its board until 2023, when he stepped down citing potential conflicts of interest. Those conflicts became more pronounced when Microsoft entered into a $650 million deal with his AI startup Inflection AI, effectively hiring its co-founder Mustafa Suleyman. The arrangement was structured as a non-acquisition, acqui-hire, allowing Microsoft to bring in top AI talent without a full takeover. Now, Hoffman is turning his attention to Manus, an AI-driven drug discovery company. The startup focuses on using artificial intelligence to accelerate the development of new treatments, particularly for cancer. Hoffman has described this as a return to 'founder mode,' signaling a hands-on role in the company's strategy and growth.

Manus: A $50 million seed-stage biotech bet

Manus has raised over $50 million through a series of seed rounds last year, according to reports. The startup counts General Catalyst among its investors, alongside Hoffman himself. Despite Hoffman's high profile, he is not the CEO of Manus. That role belongs to Dr. Siddhartha Mukherjee, a physician, biologist, and Pulitzer Prize-winning author of 'The Emperor of All Maladies: A Biography of Cancer.' Hoffman serves as a co-founder and chairman of the board, providing strategic guidance rather than day-to-day management. The company is focused on applying AI to drug discovery, a field that has seen growing interest from tech investors. Manus aims to use machine learning to identify new drug candidates, potentially reducing the time and cost of bringing treatments to market. Hoffmann has expressed excitement about the progress the startup is making, particularly in oncology.

Going 'founder mode' with Move 37 AI

In a recent episode of his podcast 'Possible,' Hoffman discussed his decision to step down from Microsoft's board with CEO Satya Nadella. He said he realized he needed to get back to 'founder mode' after seeing the progress at Manus. The startup is reportedly working on what Hoffman calls 'Move 37' AI, a reference to a famous move in the game of Go where an AI made a creative, unorthodox play that surprised human experts. In this context, 'Move 37' AI refers to artificial intelligence that can supersede human creativity in chemistry, particularly in designing new molecules for drug discovery. Hoffman believes this approach could be especially effective in combating various cancers. The concept aligns with a broader trend in AI-driven drug discovery, where models are used to generate novel chemical structures that might not occur to human researchers. Manus is positioning itself at the intersection of AI and biotechnology, aiming to accelerate the development of life-saving therapies.

Industry implications and future outlook

Hoffman's departure from Microsoft's board marks the end of an era for the company's AI strategy, though his influence will likely persist through his investments. Microsoft has deepened its ties with OpenAI, and Hoffman's exit is not expected to disrupt that relationship. However, his focus on Manus signals a growing trend of tech veterans moving into biotech, where AI is seen as a transformative force. The drug discovery market is estimated to be worth billions, and AI startups in this space have attracted significant venture capital. Manus faces competition from other AI-driven biotech firms like Recursion Pharmaceuticals and Insilico Medicine, but its leadership and funding give it a strong starting position. Hoffman's reputation and network could help the startup secure partnerships with pharmaceutical companies. For Microsoft, the board vacancy may lead to the appointment of a new director with a different expertise, potentially in cloud computing or enterprise software. The broader tech industry will be watching to see if Hoffman's 'founder mode' bet on Manus pays off.